title: Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
abstract: Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's T-cell lymphomas that present as skin lesions. Mycosis fungoides with large cell transformation has a 5-year overall survival of 32% with involved skin and 7% with extracutaneous involvement. Failure to cure advanced MF with large cell transformation and peripheral T-cell lymphoma has resulted in a search for novel targeted agents including antibodies and gene modulators. Histone deacetylase inhibitors are small molecules that seem to be particularly active for T-cell lymphoma.
authors.affiliation: Division of Internal Medicine, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mduvic@mdanderson.org.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D047630:Depsipeptides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D000077767:Panobinostat; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077337:Vorinostat
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D013449:Sulfonamides; D000077337:Vorinostat; D000077767:Panobinostat; C087123:romidepsin; C487081:belinostat
keywords: Cutaneous T-cell lymphomas; Histone deacetylase; Histone deacetylase inhibitors; T-cell lymphoma